






Memorandum – Immunology #16

To: UNCCMC Attending Physicians, Transplant Services Clinicians and Staff, Housestaff, Clinical Nurse Coordinators, Department Heads, and Supervisors

From:  John Schmitz, Ph.D.
Director, Histocompatibility Laboratory

 Eric Weimer, Ph.D.
Associate Director, Histocompatibility Laboratory

 Herbert C. Whinna, M.D., Ph.D.
Medical Director, McLendon Clinical Laboratories

Date: August 15, 2022

Subject: Changes in HLA Single Antigen Bead Testing

The Histocompatibility laboratory is introducing several changes to the One Lambda HLA Single Antigen Bead tests used from pre- and post-transplant HLA antibody testing. These changes are being made to improve testing efficiency and to reduce the frequency of false positive and negative results. No changes are being made to the specifics of ordering the tests or in reporting of results. Technical details of these changes are available by contacting Dr. Schmitz (984-974-1452) or Dr. Weimer (984-974-1451).

Because of these changes you may notice changes in the cPRA of some patients in pre-transplant samples. These changes will most notably affect “weak” (low MFI level) antibodies. Additionally you may notice changes in MFI levels in post-transplant antibody samples. Because of this, we recommend that you contact the laboratory when a significant change from previous values in post-transplant samples are noted. The laboratory will repeat the test along with the most recently tested/reported sample from that patient in order to determine if the change is assay related or a true change in HLA antibody level.